JAK2 (Janus kinase 2)

The patient had no cranial or systemic features suggestive of active GCA at diagnosis; therefore, systemic corticosteroids were deferred and close rheumatology follow-up was arranged. This case underscores the need to consider inflammatory aortitis/large-vessel vasculitis when atypical vascular findings occur in PV and highlights the value of multidisciplinary evaluation.

This case highlights that recurrent CRAO in young patients should prompt investigation for underlying hematological disorders such as ET. Early diagnosis, appropriate cytoreductive and antiplatelet therapy, and long-term multidisciplinary follow-up are essential to prevent vision loss and life-threatening thrombotic complications.

In patients with cholangiocarcinoma previously treated with immune checkpoint inhibitors (n = 20), the combination regimen achieved an ORR of 20.0% and a disease control rate of 75.0%. These findings support further development of tinengotinib, both as monotherapy and in combination with immunotherapy.

The revised International Prognostic Score of Thrombosis for Essential Thrombocythemia should be calculated to stratify thrombosis risk and guide management, including when to use low-dose aspirin and cytoreductive therapy. Hydroxyurea is the first-line agent in cytoreductive therapy. No treatments have been shown to increase survival or prevent progression to myelofibrosis or leukemia in patients with essential thrombocythemia.

In our analysis of post-MPN AMLs, we identified nine mutated loci across six genes (JAK2, IDH1/2, TP53, SRSF2, U2AF1) and linked these mutations to specific transcriptional phenotypes. Overall, LOTR-Seq provides novel insights into the evolution of post-MPN AML.

Not available.

Specifically, PA specifically disrupted the GNAI1-ARRB1 interaction, inhibiting downstream pro-survival pathways (ERK/JAK2-STAT3/mTOR) and ultimately leading to autophagic cell death in NSCLC cells. In summary, this work provides the first evidence that PA exerts anti-NSCLC effects by targeting the GNAI1/ARRB1 axis, offering a promising therapeutic strategy against advanced NSCLC.

DNMT3A-variants were enriched for single-hit clones, whereas TET2, ASXL1, JAK2, SF3B1, and SRSF2 showed enrichment for multi-hit evolution. These findings suggest precursors of hematological malignancies are identifiable prior to transformation and may facilitate early intervention strategies.

In both cases, the good biocompatibility of the designed mimetics appeared promising for evaluating signaling-dependent effects. These findings validate a multiregion, structure-guided design strategy and identify an improved SOCS3 proteomimetic scaffold with potential for targeting dysregulated JAK/STAT signaling in cancer.

Compelling emerging evidence supports an association between the JAK2 V617F somatic mutation and the formation of thoracic aortic aneurysms, with VAF acting as a valuable biomarker for aneurysm risk. However, no studies have evaluated whether increasing VAF influences aneurysm growth rate, highlighting the need for future clinical research.

Emerging combination strategies and their clinical development will be reviewed here, including investigations that pair JAKi therapy with BCL-2 family inhibitors, BET inhibitors, restored p53 cell death signals, telomerase inhibitors, PIM1 kinase inhibitors, and mutant CALR targeted therapies. While several combination clinical trials suggest improved spleen and symptom responses and the possibility of disease modification, toxicity profiles and optimal sequencing remain areas of active investigation.

While JAK2 V617F mutation was associated with distinct hematologic profiles, it was not independently linked to thrombotic risk. These findings highlight the significance of clinical comorbidities and hematologic parameters in thrombotic event occurrences in MPN patients.